The veteran psilocybin pilot triggers no change in DEA Schedule I research registration policy or bulk manufacturing quota before year-end.

The DEA (the US Drug Enforcement Administration) controls who can study psilocybin and how much of it can be legally manufactured for research. One small pilot study on veterans won't be enough to get the DEA to loosen those rules or increase the amount of psilocybin researchers are allowed to produce. Changing DEA policy requires strong, repeated evidence from well-controlled studies — and we're not there yet.

One open-label pilot doesn't move scheduling machinery. Research access adjusts slowly and only on controlled, replicated evidence.